Prescriptions for semaglutide, marketed under the names Ozempic and Wegovy, surged almost 3,000% in the U.S. from 2018 to 2022.
Encounters of gallbladder inflammation in California hospitals surged by 492% during the study period, potentially linked to the slowed digestion caused by long-term semaglutide use.
Hospital encounters in California related to acute kidney injuries rose by 18% and cases of low blood sugar (hypoglycemia) increased by 27%, suggesting these may be emerging areas of concern for semaglutide users.
We here at HQI are excited about the year ahead and continuing the collaborative work of enhancing patient safety and fostering a culture of excellence within hospitals. Our role is to support our members’ efforts toward providing the safest and highest quality care possible through education and the sharing of information and resources.